Qubigen to Attend BIO 2025 in Boston: Seeking Collaborations and Partnerships
- jonathanhall22
- Apr 23
- 3 min read
Qubigen is excited to announce our participation in the upcoming BIO International Convention 2025, taking place from June 16–19 at the Boston Convention & Exhibition Center. As one of the largest gatherings in the biotechnology industry, BIO 2025 offers a unique platform for networking, collaboration, and innovation.
Connecting with Potential Collaborators, Clients, and Data Access Partners
Qubigen will be sending a delegation of its senior staff to attend BIO 2025, and, together with the South Australian Department of State Development, Victorian delegates from State Government, and members of MTPConnect, Australia’s life sciences innovation accelerator, will be available at the Australian stand at the conference.
The purpose of the mission is to bring Qubigen’s Federated AI technology for drug design to potential collaborators, clients, or partners who are interested in targeted drug development. Qubigen’s unique AI technology can securely draw insights from multiple datasets, including Qubigen’s own proprietary database, while protecting data and IP sovereignty. Integrated virtual screening processes using molecular modelling and quantum chemistry can help identify lead candidates faster, potentially shaving years off of traditional medicinal chemistry approaches.
The Qubigen team on the ground will be actively looking for collaborators, clients, and Data Access Partners from academic institutes and from industry, to help demonstrate the benefit of Federated AI in generating novel AI molecules and optimizing lead candidates, without ever moving or seeing the contributed data.
“If you have historical or unused data for a stalled or discontinued project, and you are unable to or don’t wish to pursue drug development for your target protein, your data could still represent an extremely valuable contribution to the field of medicine. By leveraging unused data from multiple sources, we can help bring the project to fruition, with commercial rewards for data contributors. We can also assist if you have an active project but can’t find a suitable inhibitor”, explains Dr Sonya Diakiw, Founder and Chief Scientist at Qubigen.
Dr Jonathan Hall, Founder and CEO of Qubigen stated, “By securely maintaining data and IP sovereignty, institutes can combine research efforts without the inherent risk of exposing sensitive data. The consequence of this enabling technology is that pharmaceutical research can become more available to smaller groups to who otherwise do not have sufficient data to meaningfully to develop large-scale, robust and unbiased AI. Federated AI enables a global ‘collaborative-first’ approach by significantly increasing the access to health technology to a broader range of collaborators. We already have compelling results where Qubigen’s AI generated molecules exhibit better predicted binding, physicochemical, and ADMET properties, as well as improved novelty and patentability”.
Both Dr Hall and Dr Diakiw will be present among the Australian delegation to BIO 25 and eager to engage with potential collaborators, clients and Data Access Partners during the convention. Qubigen believes that collaboration is key to driving advancements in drug design, and we're looking forward to exploring opportunities that can lead to mutual growth and success.
Join Us in Boston
If you're attending BIO 2025 and are interested in discussing potential collaborations or partnerships, we'd love to meet with you. Please reach out to us to schedule a meeting during the convention. Qubigen will be using the BIO Partnering™ platform, enabling both our team and potential partners to easily schedule one-on-one meetings with each other.
Don’t hesitate, however, to reach out to us directly:
We look forward to connecting with you in Boston and exploring how we can work together.
Qubigen • Intelligent Drug Design
Qubigen combines Federated AI technology, quantum chemistry and AI drug design capabilities to create the largest global federated proprietary dataset and computational toolbox for AI driven drug design.
Bringing together Data Access partners, we are helping to crack the world's toughest diseases by fostering a collaborative federated data approach for new medicines that no single company could develop on their own.
For more information, contact enquires@qubigen.com.
